Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of AK117 (Anti-CD47 Monoclonal Antibody) in Combination With Cetuximab or AK104 (Anti-PD-1/CTLA-4 Bispecific Antibody) in Second-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT06508606 is registered in ClinicalTrials.gov with West China Hospital as lead sponsor.

NCT NCT06508606
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06508606 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of AK117 (Anti-CD47 Monoclonal Antibody) in Combination With Cetuximab or AK104 (Anti-PD-1/CTLA-4 Bispecific Antibody) in Second-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Lead sponsor
West China Hospital
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 1, 2024
Completion date
August 1, 2027
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck squamous cell carcinoma